Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,

Published bySandra Sundberg Modified over 5 years ago

Similar presentations

Presentation on theme: "Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,"— Presentation transcript:

1 Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson, C. Coddington  Fertility and Sterility  Volume 91, Issue 3, (March 2009) DOI: /j.fertnstert Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

2 Fertility and Sterility 2009 91, DOI: (10.1016/j.fertnstert.2009.01.029)
Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Download ppt "Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,"

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin- releasing hormone agonist  Bulent Ozcelik, M.D., Cagdas Turkyilmaz,

Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin- releasing hormone agonist  Bulent Ozcelik, M.D., Cagdas Turkyilmaz,
Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome

Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin- releasing hormone agonist  Bulent Ozcelik, M.D., Cagdas Turkyilmaz,

Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin- releasing hormone agonist  Bulent Ozcelik, M.D., Cagdas Turkyilmaz,
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.
Fertility and Sterility  Volume 97, Issue 3, Pages (March 2012)

Fertility and Sterility  Volume 97, Issue 3, Pages (March 2012)
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 

Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Michael M. Alper, M.D.  Fertility and Sterility 

Michael M. Alper, M.D.  Fertility and Sterility 
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Dennis J. Hand, Ph. D. , Vanessa L. Short, Ph. D. , M. P. H. , Diane J

Dennis J. Hand, Ph. D. , Vanessa L. Short, Ph. D. , M. P. H. , Diane J
Raoul Orvieto, M. D. , M. Sc. , Eduard Hod, M. D

Raoul Orvieto, M. D. , M. Sc. , Eduard Hod, M. D
Hepatitis and reproduction

Hepatitis and reproduction
A pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist 

A pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist 
Neohormones as biomarkers of reproductive health

Neohormones as biomarkers of reproductive health
Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study  Leonidas Mamas, M.D., Ph.D. 

Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study  Leonidas Mamas, M.D., Ph.D. 

Similar presentations

Ads by Google